Patrick J. Ryan
Research Subjects
Patrick J. Ryan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Steven E. Riechman
Muscle Biology Laboratory, Department of Kinesiology and Sports Management Texas A&M University College Station Texas USA
3 shared publicationsBethany C. Guerra
Muscle Biology Laboratory, Department of Kinesiology and Sports Management Texas A&M University College Station Texas USA
2 shared publications- James D. Fluckey
Department of Kinesiology and Sport Management, Texas A&M University, College Station, TX, USA
2 shared publications Mariana Janini Gomes
Muscle Biology Laboratory, Department of Kinesiology and Sports Management Texas A&M University College Station Texas USA
2 shared publicationsPeter P. Nghiem
Department of Veterinary Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences Texas A&M University College Station Texas USA
2 shared publicationsSelina Uranga
Muscle Biology Laboratory, Department of Kinesiology and Sports Management Texas A&M University College Station TX USA
2 shared publications
Latest Publications
- Open Access
- 2 May 2026
- Published by Wiley in FASEB BioAdvances
- Vol. 8 (5)
MicroRNA 15a and 16 Regulate Proteostasis in Non‐Small Cell Lung Cancer
Aberrant anabolic activity is critical to tumor biology; however, much remains to be learned about the regulators of protein anabolism in cancer and how this regulation may affect cancer pathophysiology. MicroRNA (miRNA), a family of small nucleotide regulatory molecules, may serve as a potential source of proteostatic regulation. Here, we examined the ability of two co‐transcribed miRNA species, miR15a and miR16 (jointly described as miR15a/16) to regulate protein handling and pathophysiology in non‐small cell lung cancer (NSCLC). We found that miR15a/16 regulates genes in numerous metabolic and pathological pathways, including those related to protein metabolism. Transfection of cellular models of NSCLC with miR15a/16 mimetics caused reductions in both cell growth and protein synthesis rates. These findings indicate that miR15a/16 acts as regulators of protein anabolism in NSCLC, serving as novel metabolic regulators and potential clinical therapeutic targets for malignant lung cancer.
- 2 May 2026
- Published by Wiley in FASEB BioAdvances
- Vol. 8 (5)
Open AccessMicroRNA 15a and 16 Regulate Proteostasis in Non‐Small Cell Lung Cancer
Aberrant anabolic activity is critical to tumor biology; however, much remains to be learned about the regulators of protein anabolism in cancer and how this regulation may affect cancer pathophysiology. MicroRNA (miRNA), a family of small nucleotide regulatory molecules, may serve as a potential source of proteostatic regulation. Here, we examined the ability of two co‐transcribed miRNA species, miR15a and miR16 (jointly described as miR15a/16) to regulate protein handling and pathophysiology in non‐small cell lung cancer (NSCLC). We found that miR15a/16 regulates genes in numerous metabolic and pathological pathways, including those related to protein metabolism. Transfection of cellular models of NSCLC with miR15a/16 mimetics caused reductions in both cell growth and protein synthesis rates. These findings indicate that miR15a/16 acts as regulators of protein anabolism in NSCLC, serving as novel metabolic regulators and potential clinical therapeutic targets for malignant lung cancer.
- Open Access
- 24 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1005081
Obesity and cancer: Methodological frontiers for mechanistic discoveries
Why obesity increases cancer risk has long remained a biological mystery. Rapid advances in statistical and analytical methods are now opening the door to mechanistic discoveries that may finally help resolve this question.
- 24 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1005081
Open AccessObesity and cancer: Methodological frontiers for mechanistic discoveries
Why obesity increases cancer risk has long remained a biological mystery. Rapid advances in statistical and analytical methods are now opening the door to mechanistic discoveries that may finally help resolve this question.
- Open Access
- 9 October 2025
- Published by Wiley in FEBS Open Bio
- Vol. 16 (3) , 570-583
ATG4B is required for mTORC1 ‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer
The complex interplay of metabolic signaling networks is critical to the pathophysiology of lung cancer. The anabolic mTORC1 kinase and catabolic process of autophagy are key among these regulatory pathways. While their relationship has long been viewed as a matter of simple inhibition, with mTORC1 as a negative regulator of autophagy, new evidence suggests that this relationship may be more nuanced than previously described. Here, we demonstrate that an autophagy‐related, ATG4B, is required for mTORC1 activity and is associated with negative clinical outcomes in non‐small cell lung cancer (NSCLC). Targeting ATG4B in vitro suppresses cell proliferation, protein synthesis rates, and mTORC1 signaling in a cellular model of NSCLC. In contrast, overexpressing the ATG4B protease in healthy models of lung tissue increased mTORC1 kinase activity in healthy lung cell models, indicating that an increase in ATG4B is sufficient to drive cellular anabolic signaling. Finally, we found that ATG4B expression is high in NSCLC patient tumors, is elevated in early‐stage cancer, and predicts survival in lung adenocarcinoma patients. Taken together, our results demonstrate that ATG4B is required for anabolic behavior in NSCLC, indicating that the autophagic cascade may be a required input for mTORC1 activity and cellular anabolism in lung cancer. These results have implications for the field of cancer biology more broadly, as they indicate that the far from being a simple target of mTORC1, the autophagic cascade may serve as a requisite input for anabolic signaling, casting new light on the relationship between these processes in cancer pathophysiology. [Correction added on 25 February 2026, after first online publication: 9th sentence has been revised as “Targeting ATG4B in vitro suppresses cell proliferation, protein synthesis rates, and mTORC1 signaling in a cellular model of NSCLC”].
- 9 October 2025
- Published by Wiley in FEBS Open Bio
- Vol. 16 (3) , 570-583
Open AccessATG4B is required for mTORC1 ‐mediated anabolic activity and is associated with clinical outcomes in non‐small cell lung cancer
The complex interplay of metabolic signaling networks is critical to the pathophysiology of lung cancer. The anabolic mTORC1 kinase and catabolic process of autophagy are key among these regulatory pathways. While their relationship has long been viewed as a matter of simple inhibition, with mTORC1 as a negative regulator of autophagy, new evidence suggests that this relationship may be more nuanced than previously described. Here, we demonstrate that an autophagy‐related, ATG4B, is required for mTORC1 activity and is associated with negative clinical outcomes in non‐small cell lung cancer (NSCLC). Targeting ATG4B in vitro suppresses cell proliferation, protein synthesis rates, and mTORC1 signaling in a cellular model of NSCLC. In contrast, overexpressing the ATG4B protease in healthy models of lung tissue increased mTORC1 kinase activity in healthy lung cell models, indicating that an increase in ATG4B is sufficient to drive cellular anabolic signaling. Finally, we found that ATG4B expression is high in NSCLC patient tumors, is elevated in early‐stage cancer, and predicts survival in lung adenocarcinoma patients. Taken together, our results demonstrate that ATG4B is required for anabolic behavior in NSCLC, indicating that the autophagic cascade may be a required input for mTORC1 activity and cellular anabolism in lung cancer. These results have implications for the field of cancer biology more broadly, as they indicate that the far from being a simple target of mTORC1, the autophagic cascade may serve as a requisite input for anabolic signaling, casting new light on the relationship between these processes in cancer pathophysiology. [Correction added on 25 February 2026, after first online publication: 9th sentence has been revised as “Targeting ATG4B in vitro suppresses cell proliferation, protein synthesis rates, and mTORC1 signaling in a cellular model of NSCLC”].
- Open Access
- 1 February 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (2) , C670-C678
MCF7 breast cancer anabolic capacity reduced with CRISPR/Cas9-mediated stable overexpression of DEPTOR
We identify DEPTOR as a predictor of mortality in breast cancer and show that precision gene editing to restore DEPTOR expression in breast cancer slows cell growth by inhibiting mTOR activity.
- 1 February 2025
- Published by American Physiological Society in American Journal of Physiology-Cell Physiology
- Vol. 328 (2) , C670-C678
Open AccessMCF7 breast cancer anabolic capacity reduced with CRISPR/Cas9-mediated stable overexpression of DEPTOR
We identify DEPTOR as a predictor of mortality in breast cancer and show that precision gene editing to restore DEPTOR expression in breast cancer slows cell growth by inhibiting mTOR activity.